JP2014517038A5 - - Google Patents

Download PDF

Info

Publication number
JP2014517038A5
JP2014517038A5 JP2014515934A JP2014515934A JP2014517038A5 JP 2014517038 A5 JP2014517038 A5 JP 2014517038A5 JP 2014515934 A JP2014515934 A JP 2014515934A JP 2014515934 A JP2014515934 A JP 2014515934A JP 2014517038 A5 JP2014517038 A5 JP 2014517038A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
wound
skin
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014515934A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014517038A (ja
JP6005736B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/042165 external-priority patent/WO2012174056A1/en
Publication of JP2014517038A publication Critical patent/JP2014517038A/ja
Publication of JP2014517038A5 publication Critical patent/JP2014517038A5/ja
Application granted granted Critical
Publication of JP6005736B2 publication Critical patent/JP6005736B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014515934A 2011-06-13 2012-06-13 Il−12を用いる皮膚損傷の軽減 Active JP6005736B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161496472P 2011-06-13 2011-06-13
US61/496,472 2011-06-13
US201161528053P 2011-08-26 2011-08-26
US61/528,053 2011-08-26
PCT/US2012/042165 WO2012174056A1 (en) 2011-06-13 2012-06-13 Mitigation of cutaneous injury with il-12

Publications (3)

Publication Number Publication Date
JP2014517038A JP2014517038A (ja) 2014-07-17
JP2014517038A5 true JP2014517038A5 (https=) 2015-07-30
JP6005736B2 JP6005736B2 (ja) 2016-10-12

Family

ID=47357436

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014515934A Active JP6005736B2 (ja) 2011-06-13 2012-06-13 Il−12を用いる皮膚損傷の軽減

Country Status (5)

Country Link
US (1) US9925246B2 (https=)
EP (1) EP2718456B1 (https=)
JP (1) JP6005736B2 (https=)
CA (1) CA2839261A1 (https=)
WO (1) WO2012174056A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3484500A4 (en) * 2016-07-18 2020-01-08 Neumedicines, Inc Uses of il-12 as a replacement immunotherapeutic
JP7045671B2 (ja) * 2018-11-12 2022-04-01 有限会社バイオ研 皮膚塗布用の皮膚創傷治癒促進組成物、その製造方法、及び創傷被覆材
JP7448137B2 (ja) * 2020-03-10 2024-03-12 日本ゼトック株式会社 アクチン重合促進剤
WO2023009439A1 (en) * 2021-07-30 2023-02-02 The Board Of Trustees Of The Leland Stanford Junior University Mechanotransduction disruption mediation in skin grafting methods and compositions for use in practicing the same

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US6683046B1 (en) 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
US5573764A (en) 1994-01-21 1996-11-12 Genetics Institute, Inc. Use of interleukin-12 to prevent graft versus host disease
JP2000510813A (ja) 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Il−12用処方
US5853714A (en) 1995-03-27 1998-12-29 Genetics Institute, Inc. Method for purification of IL-12
AU761520B2 (en) * 1998-09-15 2003-06-05 Genetics Institute, Llc Treatment of Kaposi's Sarcoma with IL-12
US7052685B1 (en) * 1998-10-15 2006-05-30 Trustees Of The University Of Pennsylvania Methods for treatment of cutaneous T-cell lymphoma
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
US7763256B2 (en) 2002-12-23 2010-07-27 William Marsh Rice University Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
JP4902961B2 (ja) 2002-12-23 2012-03-21 シェーリング コーポレイション 哺乳動物サイトカインの用途;関連試薬
US7939058B2 (en) * 2003-07-03 2011-05-10 University Of Southern California Uses of IL-12 in hematopoiesis
EP1641431B1 (en) * 2003-07-03 2018-01-10 University Of Southern California Uses of il-12 for reducing the toxicity of chemo- and/or radio-therapy
EP1793859B1 (en) 2004-08-20 2009-03-25 Smithkline Beecham Corporation Treatment of oral and intestinal mucositis by administering human il-18
WO2008067042A2 (en) 2006-10-10 2008-06-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Modeling wound healing
US20100330046A1 (en) * 2009-05-21 2010-12-30 Stratatech Corporation Human skin substitutes expressing il-12

Similar Documents

Publication Publication Date Title
Zhang et al. Scarless wound healing programmed by core-shell microneedles
BR112012024590A2 (pt) métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos
HRP20120349T1 (hr) Formulacija glatiramer acetata smanjenog volumenai postupci davanja
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
JP2006117700A5 (https=)
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
MX369385B (es) Productos para cicatrizar heridas tisulares.
AR099078A2 (es) Un medicamento que comprende acetato de glatiramer
EA200971053A1 (ru) Способы лечения кожных язв
WO2008064299A3 (en) Methods of reducing porcine circovirus-associated disease outbreaks
MX2014001050A (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero.
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
RU2015103107A (ru) Комбинированная композиция
EP4477267A3 (en) Collagen peptide-based medicament compositions for use in the treatment of ocular diseases, disorders or wounds
JP2014139255A5 (https=)
JP2014517038A5 (https=)
Jing et al. Effects of 180 mT static magnetic fields on diabetic wound healing in rats
TN2015000480A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
PH12015502128A1 (en) Novel dosing regimens of celgosivir for the treatment of dengue
JP2013520447A5 (https=)
JP2003528919A5 (https=)
FI3648788T3 (fi) Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää
MX336278B (es) Composiciones y metodos para la prevencion y el tratamiento de heridas.
BR112012000773A2 (pt) Método para o tratamento de pelo menos uma condição escolhida entre dor, inflamação e febre em pacientes humanos, método para o tratamento de pacientes humanos, método para o tratamento de pelo menos uma condição escolhida entre dor, inflamação e febre em pacientes criticamente doentes, e método para o tratamento de pelo menos uma condição escolhida entre dor, inflamação e febre em pacientes criticamente doentes com risco aumentado de eventos cardiovasculares
WO2014075203A1 (es) Nanopartículas con polímero biodegradable y biocompatible plga cargadas con el fármaco de uso humano pentoxfilina